e-Therapeutics PLC's (LON:ETX) chief scientific officer Alan Whitmore speaks to Proactive London's Andrew Scott after announcing they've begun experimental testing on the first set of compounds for the treatment of coronavirus (COVID-19) identified using its proprietary network-driven drug discovery (NDD) platform.
He says the initial compound set, which has the potential to address both viral replication and the associated excessive immune response, will be tested by WuXi AppTec utilising its relevant cell-based assays.